Medication info

Mcipeolmin Sustained Release Tablet 10/100/1000 mg (Empagliflozin, Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletSitagliptin Phosphate Hydrate›128.5mg / 1 tabletEmpagliflozin L-Proline›12.55mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Light blue, double convex, oval-shaped sustained release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500917 · Approved 2025.04.16

Summary

Main use
Improves blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily. For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improves blood glucose control in adults with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with diet and exercise to effectively improve blood sugar control in adult patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily. For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication may rarely cause serious hypersensitivity reactions due to the sitagliptin component. Such reactions may include anaphylaxis, angioedema, and severe rash or exfoliative disorders on the skin; therefore, if symptoms occur, the use should be stopped immediately and medical attention should be sought. Additionally, sitagliptin may cause acute pancreatitis, so if symptoms such as abdominal pain, nausea, or vomiting occur after taking, immediate consultation with a physician is advised. The metformin component may rarely cause lactic acidosis, a serious metabolic side effect. Lactic acidosis is accompanied by symptoms such as muscle pain, respiratory distress, weakness, and abdominal pain, and immediate treatment is needed if it occurs, necessitating caution. This medication should not be administered to patients with type 1 diabetes, severe renal impairment, or acute heart failure. Temporary discontinuation of use is advised in cases of severe infection, dehydration, or around surgical procedures. Patients with impaired kidney function should regularly undergo kidney function tests as the components are excreted through the kidneys, and this medication should not be used if kidney function is significantly compromised. As this medication poses a risk of hypoglycemia, careful monitoring of blood sugar changes is important, especially when taken with insulin or sulfonylurea medications. During treatment, gastrointestinal disturbances, headaches, and infections may occur, and there may be an increased risk of genital infections and urinary tract infections, so it is important to consult with a doctor if symptoms appear. Elderly patients over 75 years of age or those at risk of fluid volume loss should be aware of symptoms of dehydration or hypotension, and can temporarily discontinue use if necessary. This medication should be avoided in patients with impaired liver function, as excessive alcohol consumption may increase the risk of side effects. Care should be taken when driving or operating machinery due to the risk of hypoglycemia. Lastly, while taking this medication, it is important to regularly check blood tests and health status to monitor for any adverse reactions or side effects.

Side effects

Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, influenza, anal abscess, perforated appendicitis, periodontal disease, dental abscess, vaginal infection, dyspepsia, upper abdominal pain, hemorrhoids, dry mouth, alcoholic gastritis, erosive gastritis, hematemesis, nausea, chest pain, asthenia, fatigue, increased blood glucose, weight loss, elevated serum creatine phosphokinase, eyelid spasms, diabetic retinopathy, keratitis, vitreous hemorrhage, transitional cell carcinoma of the bladder, prostate cancer, renal cell carcinoma, angular blockage, left ventricular hypertrophy, hyperglycemia, hypoglycemia, vulvar pruritus, diaphoresis, dermatitis, biliary obstruction, forearm fracture, headache, insomnia, increased urination, sleep apnea syndrome, removal of artificial fixation devices, vomiting, changes in bowel habits, colitis, dental caries, enteritis, nasopharyngitis, coronavirus infection, Helicobacter infection, otitis externa, cataract, borderline glaucoma, endocrine eye disease, arthralgia, lumbar spinal stenosis, spinal stenosis, cough, eosinophilic bronchitis, oropharyngeal pain, contusion, metatarsal fracture, radiculopathy, thalamic infarction, breast mass, keloid scar, rash, aneurysm, hypotension, ventricular ectopic beats, gill pouch, vulvovaginitis, balanitis, urinary tract infection, perineal necrosis, constipation, taste impairment, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, erythema, pruritus, urticaria, rash, severe and disabling arthralgia, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, headache, upper respiratory infection, peripheral edema, nasopharyngitis, headache, hypoglycemia, acute renal failure, soft tissue infection, appendiceal abscess, appendicitis, meningitis, chronic otitis media, peritonsillar abscess, pneumonia, pulmonary tuberculosis, acute pyelonephritis, sepsis, subcutaneous abscess, tubo-ovarian abscess, vestibular neuritis, acute cholecystitis, autoimmune hepatitis, cholelithiasis, anemia, lymphadenopathy, hypothyroidism, thyroid nodule, anxiety, depression, sleep disorders, angina, Prinzmetal's angina, coronary artery disease, deep vein thrombosis, arteriosclerosis, diabetic vascular complications, peripheral arterial occlusive disease, unstable angina, hypertension, insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is advisable to maintain the storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Light blue, double convex, oval-shaped sustained release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.